Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
Top Cited Papers
Open Access
- 2 April 2020
- journal article
- editorial
- Published by Elsevier BV in Trends in Immunology
- Vol. 41 (5), 355-359
- https://doi.org/10.1016/j.it.2020.03.007
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R01AI137472, R01AI139092)
This publication has 17 references indexed in Scilit:
- An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategiesEmerging Microbes & Infections, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Application of a Phage Cocktail for Control of Salmonella in Foods and Reducing BiofilmsViruses, 2019
- Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding DomainViruses, 2019
- MERS-CoV spike protein: a key target for antiviralsEmerging Therapeutic Targets, 2016
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus ChallengeJournal of Virology, 2008
- Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodiesProceedings of the National Academy of Sciences of the United States of America, 2007
- Cross-Neutralization of Human and Palm Civet Severe Acute Respiratory Syndrome Coronaviruses by Antibodies Targeting the Receptor-Binding Domain of Spike ProteinThe Journal of Immunology, 2006
- Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor associationProceedings of the National Academy of Sciences of the United States of America, 2004